Swedish Orphan Biovitrum AB (publ) (BIT:1SOBI)

Market Cap	9.27B
Revenue (ttm)	2.27B
Net Income (ttm)	339.06M
Shares Out	n/a
EPS (ttm)	0.98
PE Ratio	27.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	26.40
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	n/a
Earnings Date	Mar 31, 2025

About BIT:1SOBI

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,840
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1SOBI

Financial Performance

In 2024, BIT:1SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK